Ignite Creation Date:
2025-12-24 @ 1:42 PM
Ignite Modification Date:
2026-02-20 @ 6:42 PM
Study NCT ID:
NCT02984995
Status:
COMPLETED
Last Update Posted:
2020-02-17
First Post:
2016-12-05
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation
Sponsor:
Daiichi Sankyo Co., Ltd.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AC220-A-J201
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |